Alnylam Pharmaceuticals (ALNY) shows strong price momentum, hitting new all-time highs on Aug. 11. ・ALNY has a 100% technical ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $406.0, a high ...

Despite battling drugs from BridgeBio and Pfizer, Amvuttra beat Wall Street expectations with results Alnylam’s CEO claimed were “not a flash in the pan.” ...

Buying $100 In ALNY: If an investor had bought $100 of ALNY stock 10 years ago, it would be worth $385.28 today based on a price of $433.41 for ALNY at the time of writing.

Company to Webcast Investor Event on August 30, 2025, at 1:00 p.m. EDT (7:00 pm CEST)- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that ...

Alnylam Pharma has an analyst consensus of Strong Buy, with a price target consensus of $317.10, a 18.95% upside from current levels. In a report released today, Scotiabank also maintained a Buy ...

Alnylam Pharmaceuticals, Inc. ( NASDAQ:ALNY ) shareholders will have a reason to smile today, with the analysts ...

Q2 2025 Earnings Call Transcript July 31, 2025 Alnylam Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is ...

Alnylam Pharmaceuticals, Inc. has a 12 month low of $205.87 and a 12 month high of $333.70. The stock’s 50 day moving average is $294.96 and its two-hundred day moving average is $266.07.

Alnylam Pharma (ALNY) Company Description: Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics.

Alnylam Pharmaceuticals, Inc. has a 52 week low of $141.98 and a 52 week high of $304.39. The company has a debt-to-equity ratio of 15.27, a quick ratio of 2.71 and a current ratio of 2.78.

Contacts Alnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media) 617-682-4340 Josh Brodsky (Investors) 617-551-8276 ...